CYCLO THERAPEUTICS INC (CYTH) Fundamental Analysis & Valuation

NASDAQ:CYTH • US23254X2018

Current stock price

0.7206 USD
+0.01 (+1.39%)
At close:
0.7199 USD
0 (-0.1%)
After Hours:

This CYTH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CYTH Profitability Analysis

1.1 Basic Checks

  • In the past year CYTH has reported negative net income.
  • CYTH had a negative operating cash flow in the past year.
  • CYTH had negative earnings in each of the past 5 years.
  • CYTH had a negative operating cash flow in each of the past 5 years.
CYTH Yearly Net Income VS EBIT VS OCF VS FCFCYTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

  • With a Return On Assets value of -472.02%, CYTH is not doing good in the industry: 96.65% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -472.02%
ROE N/A
ROIC N/A
ROA(3y)-196.91%
ROA(5y)-167.39%
ROE(3y)-876.42%
ROE(5y)-703.18%
ROIC(3y)N/A
ROIC(5y)N/A
CYTH Yearly ROA, ROE, ROICCYTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K

1.3 Margins

  • CYTH has a Gross Margin of 91.24%. This is amongst the best in the industry. CYTH outperforms 91.90% of its industry peers.
  • In the last couple of years the Gross Margin of CYTH has remained more or less at the same level.
  • CYTH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.5%
GM growth 5Y0.39%
CYTH Yearly Profit, Operating, Gross MarginsCYTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. CYTH Health Analysis

2.1 Basic Checks

  • CYTH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CYTH has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for CYTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CYTH Yearly Shares OutstandingCYTH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
CYTH Yearly Total Debt VS Total AssetsCYTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

  • Based on the Altman-Z score of -45.56, we must say that CYTH is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -45.56, CYTH is not doing good in the industry: 93.13% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -45.56
ROIC/WACCN/A
WACC10.15%
CYTH Yearly LT Debt VS Equity VS FCFCYTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M

2.3 Liquidity

  • CYTH has a Current Ratio of 0.17. This is a bad value and indicates that CYTH is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CYTH's Current ratio of 0.17 is on the low side compared to the rest of the industry. CYTH is outperformed by 96.48% of its industry peers.
  • CYTH has a Quick Ratio of 0.17. This is a bad value and indicates that CYTH is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.16, CYTH is doing worse than 96.30% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.17
Quick Ratio 0.16
CYTH Yearly Current Assets VS Current LiabilitesCYTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. CYTH Growth Analysis

3.1 Past

  • CYTH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.87%, which is quite impressive.
  • CYTH shows a decrease in Revenue. In the last year, the revenue decreased by -8.86%.
  • Measured over the past years, CYTH shows a small growth in Revenue. The Revenue has been growing by 1.28% on average per year.
EPS 1Y (TTM)44.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.34%
Revenue 1Y (TTM)-8.86%
Revenue growth 3Y6.15%
Revenue growth 5Y1.28%
Sales Q2Q%-52.98%

3.2 Future

  • Based on estimates for the next years, CYTH will show a very strong growth in Earnings Per Share. The EPS will grow by 20.87% on average per year.
  • Based on estimates for the next years, CYTH will show a very strong growth in Revenue. The Revenue will grow by 106.48% on average per year.
EPS Next Y56.84%
EPS Next 2Y25.49%
EPS Next 3Y20.87%
EPS Next 5YN/A
Revenue Next Year-41.47%
Revenue Next 2Y-14.64%
Revenue Next 3Y106.48%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CYTH Yearly Revenue VS EstimatesCYTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M
CYTH Yearly EPS VS EstimatesCYTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

1

4. CYTH Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CYTH. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYTH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYTH Price Earnings VS Forward Price EarningsCYTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYTH Per share dataCYTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CYTH's earnings are expected to grow with 20.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.49%
EPS Next 3Y20.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CYTH Dividend Analysis

5.1 Amount

  • CYTH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CYTH Fundamentals: All Metrics, Ratios and Statistics

CYCLO THERAPEUTICS INC

NASDAQ:CYTH (3/25/2025, 8:00:01 PM)

After market: 0.7199 0 (-0.1%)

0.7206

+0.01 (+1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-25
Earnings (Next)05-13
Inst Owners11.45%
Inst Owner Change0%
Ins Owners8.13%
Ins Owner Change0%
Market Cap23.72M
Revenue(TTM)870.80K
Net Income(TTM)-24.80M
Analysts77.78
Price Target0.97 (34.61%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-50.89%
Min EPS beat(2)-68.96%
Max EPS beat(2)-32.83%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-38.61%
Min Revenue beat(2)-54.92%
Max Revenue beat(2)-22.3%
Revenue beat(4)0
Avg Revenue beat(4)-39.05%
Min Revenue beat(4)-54.92%
Max Revenue beat(4)-22.3%
Revenue beat(8)1
Avg Revenue beat(8)-43.22%
Revenue beat(12)2
Avg Revenue beat(12)-33.37%
Revenue beat(16)3
Avg Revenue beat(16)-29.66%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 27.24
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.92
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.68
OCFYN/A
SpS0.03
BVpS-0.41
TBVpS-0.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -472.02%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.24%
FCFM N/A
ROA(3y)-196.91%
ROA(5y)-167.39%
ROE(3y)-876.42%
ROE(5y)-703.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.5%
GM growth 5Y0.39%
F-Score3
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.17
Quick Ratio 0.16
Altman-Z -45.56
F-Score3
WACC10.15%
ROIC/WACCN/A
Cap/Depr(3y)70.81%
Cap/Depr(5y)142.49%
Cap/Sales(3y)0.98%
Cap/Sales(5y)1.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.34%
EPS Next Y56.84%
EPS Next 2Y25.49%
EPS Next 3Y20.87%
EPS Next 5YN/A
Revenue 1Y (TTM)-8.86%
Revenue growth 3Y6.15%
Revenue growth 5Y1.28%
Sales Q2Q%-52.98%
Revenue Next Year-41.47%
Revenue Next 2Y-14.64%
Revenue Next 3Y106.48%
Revenue Next 5YN/A
EBIT growth 1Y-27.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-50.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.22%
OCF growth 3YN/A
OCF growth 5YN/A

CYCLO THERAPEUTICS INC / CYTH Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CYCLO THERAPEUTICS INC (CYTH) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CYTH.


What is the valuation status for CYTH stock?

ChartMill assigns a valuation rating of 1 / 10 to CYCLO THERAPEUTICS INC (CYTH). This can be considered as Overvalued.


How profitable is CYCLO THERAPEUTICS INC (CYTH) stock?

CYCLO THERAPEUTICS INC (CYTH) has a profitability rating of 1 / 10.


What is the expected EPS growth for CYCLO THERAPEUTICS INC (CYTH) stock?

The Earnings per Share (EPS) of CYCLO THERAPEUTICS INC (CYTH) is expected to grow by 56.84% in the next year.